Christoph Seidel
Priv.-Doz. Dr. med.
Christoph Seidel
  • Functional senior physician
  • Medical Specialist in Internal Medicine and Hematology and Oncology
Working area



O24 , 5th Floor
German (Mother tongue)

Areas of expertise



  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

Current pharmacotherapy for testicular germ cell cancer
Alsdorf W, Seidel C, Bokemeyer C, Oing C
EXPERT OPIN PHARMACO. 2019;20(7):837-850.

Therapeutic approaches for refractory germ cell cancer
Oing C, Seidel C, Bokemeyer C
EXPERT REV ANTICANC. 2018;18(4):389-397.

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors
Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Bokemeyer C
EUR J CANCER. 2018;94:16-25.

Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
Dulz S, Asselborn N, Dieckmann K, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger L, Alsdorf W, Mankichian B, Meyer C, Vetterlein M, Gild P, Ludwig T, Soave A, Schriefer P, Becker A, Ahyai S, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun F, Kluth L
J CANCER RES CLIN. 2017;143(7):1319-1325.

Specific Characteristics of Patients with Advanced Genitourinary Cancer Receiving Specialized Inpatient Palliative Care
Iversen K, Oechsle K, Oing C, Bokemeyer C, Seidel C
ONCOL RES TREAT. 2017;40(10):609-614.

Cisplatin-refraktäre Keimzelltumoren: Resistenzmechanismen − Therapiestandards − neue Entwicklungen
Oing C, Seidel C, Alsdorf W, Bokemeyer C
ONKOLOGE. 2017;23(2):123-128.

Male Extragonadal Germ Cell Tumors of the Adult
Busch J, Seidel C, Zengerling F
ONCOL RES TREAT. 2016;39(3):140-4.

Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Ivanyi P, Koenig J, Trummer A, Busch J, Seidel C, Reuter C, Ganser A, Grünwald V
WORLD J UROL. 2016;34(7):909-15.

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature
Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C
J UROLOGY. 2016;195(2):254-63.

Pharmacotherapeutic treatment of germ cell tumors - standard of care and recent developments
Oing C, Seidel C, von Amsberg G, Oechsle K, Bokemeyer C
EXPERT OPIN PHARMACO. 2016;17(4):545-60.

Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care-Registry data from an outcomes research project of the German Testicular Cancer Study Group
Seidel C, Oechsle K, Lorch A, Dieing A, Hentrich M, Hornig M, Grünwald V, Cathomas R, Meiler J, de Wit M, Bokemeyer C
UROL ONCOL-SEMIN ORI. 2016;34(4):167.e21-8.

Metastatic Germ Cell Cancer: The Intermediate-Prognosis Risk Category
Bokemeyer C, Seidel C
2015. Diagnosis and Management of Testicular Cancer. Krege S (eds.). 1. ed. Springer, 55-64.

Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma
Busch J, Seidel C, Goranova I, Erber B, Peters R, Friedersdorff F, Magheli A, Miller K, Grünwald V, Weikert S
EUR J CANCER. 2014;50(3):563-9.

DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies
Peters I, Dubrowinskaja N, Abbas M, Seidel C, Kogosov M, Scherer R, Gebauer K, Merseburger A, Kuczyk M, Grünwald V, Serth J
PLOS ONE. 2014;9(3):e91440.

Retrospective Comparison of Triple-sequence Therapies in Metastatic Renal Cell Carcinoma.
Busch J, Seidel C, Erber B, Issever A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Grünwald V, Weikert S
EUR UROL. 2013;64(1):62-70.

Tumor shrinkage during VEGF inhibitor therapy as an independent predictor of PFS and OS in renal cell carcinoma (RCC)
Busch J, Weikert S, Seidel C
J CLIN ONCOL. 2013;31(6_suppl):423.

Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder
Eggers H, Seidel C, Schrader A, Lehmann R, Wegener G, Kuczyk M, Steffens S
MED ONCOL. 2013;30(4):705.

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
Seidel C, Busch J, Weikert S, Steffens S, Bokemeyer C, Grünwald V
BRIT J CANCER. 2013;109(12):2998-3004.

Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma
Stein B, Schrader A, Wegener G, Seidel C, Kuczyk M, Steffens S
BMC CANCER. 2013;13:101.

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C, Busch J, Weikert S, Steffens S, Fenner M, Ganser A, Grünwald V
EUR J CANCER. 2012;48(7):1023-1030.

Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).
Seidel C, Fenner M, Länger F, Bantel H, Ganser A, Grünwald V
BMC CANCER. 2012;12:186.

Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study.
Steffens S, Janssen M, Roos F, Becker F, Schumacher S, Seidel C, Wegener G, Thüroff J, Hofmann R, Stöckle M, Siemer S, Schrader M, Hartmann A, Kuczyk M, Junker K, Schrader A
EUR J CANCER. 2012;48(15):2347-2352.

Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients.
Steffens S, Köhler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk M, Schrader A
BMC CANCER. 2012;12:399.

Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors
Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S
EUR UROL. 2011;60(6):1163-70.

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V
BMC CANCER. 2011;11:295.

Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC
Grünwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, Reuter C, Ganser A, Johannsen M
ONKOLOGIE. 2011;34(6):310-4.

Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients
Seidel C, Fenner M, Merseburger A, Reuter C, Ivanyi P, Länger F, Ganser A, Grünwald V
WORLD J UROL. 2011;29(3):355-60.

Retrospective analyses of patient characteristics having predictive impact on survival under everolimus
Seidel C, Fenner M, Reuter C, Merseburger A, Ganser A, Grünwald V
ONKOLOGIE. 2011;34(3):111-4.

Einsatz von mTOR-Inhibitoren bei soliden Tumoren
Seidel C, Grünwald V
Med Monatsschr Pharm. 2011;34(4):116-26; quiz 127-8.

Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?
Steffens S, Grünwald V, Ringe K, Seidel C, Eggers H, Schrader M, Wacker F, Kuczyk M, Schrader A
ONCOLOGIST. 2011;16(11):1565-71.

The role of diabetes mellitus in localized and metastatic renal cell carcinoma
Steffens S, von Klot C, Eggers H, Seidel C, Wegener G, Schrader M, Kuczyk M, Schrader A
J Diabetes Mellitus. 2011;1(4):104-108.

Recall pneumonitis during systemic treatment with sunitinib
Seidel C, Janssen S, Karstens J, Welte T, Morgan M, Ganser A, Grünwald V
ANN ONCOL. 2010;21(10):2119-20.

Letzte Aktualisierung aus dem FIS: 18.08.2019 - 05:17 Uhr